Benfotiamine

Last Updated: November 17 2022

Benfotiamine is a relative of the vitamin Thiamine (B1) that appears to have a therapeutic role in pain reduction and diabetic complications (neuropathies and nephropathies); confers bioavailable Vitamin B1 after oral ingestion.

Benfotiamine is most often used for

What else is Benfotiamine known as?
Note that Benfotiamine is also known as:
  • S-{(Z)-2-{(4-amino-2-methylpyrimidin-5-yl) methyl-formylamino}-5-phosphonooxypent-2-en-3-yl} benzenecarbothioate
Benfotiamine should not be confused with:
  • Sulbutiamine (a molecule made from two Thiamin molecules; very different actions though)
Dosage information

Benfotiamine is commonly taken at the oral dose of 300-600mg over the course of the day, usually in two divided doses with meals (150mg or 300mg twice daily).

Join our supplement information course

Enter your email for a FREE five-day course on supplements. Get only the information that’s 100% backed by science. We take an independent and unbiased approach to figure out what works (and what’s a waste of time and money).

Examine is the only 100% independent company in the nutrition and supplement industry. While everyone else sells supplements and works with sponsors, we exclusively analyze research.

    The only 100% independent company. While everyone sells supplements, we only analyze research.

    Examine Database: Benfotiamine
    What works and what doesn't?

    Unlock the full potential of Examine

    Get started

    Don't miss out on the latest research

    Become an Examine Insider for FREE to stay on top of the latest nutrition research, supplement myths, and more

      References
      2.^WADA T, TAKAGI H, MINAKAMI H, HAMANAKA W, OKAMOTO K, ITO A, SAHASHI YA new thiamine derivative, S-benzoylthiamine O-monophosphateScience.(1961 Jul 21)
      5.^Hurt JK, Coleman JL, Fitzpatrick BJ, Taylor-Blake B, Bridges AS, Vihko P, Zylka MJProstatic Acid phosphatase is required for the antinociceptive effects of thiamine and benfotiaminePLoS One.(2012)
      6.^Bitsch R, Wolf M, Möller J, Heuzeroth L, Grüneklee DBioavailability assessment of the lipophilic benfotiamine as compared to a water-soluble thiamin derivativeAnn Nutr Metab.(1991)
      7.^Balakumar P, Rohilla A, Krishan P, Solairaj P, Thangathirupathi AThe multifaceted therapeutic potential of benfotiaminePharmacol Res.(2010 Jun)
      8.^Pan X, Gong N, Zhao J, Yu Z, Gu F, Chen J, Sun X, Zhao L, Yu M, Xu Z, Dong W, Qin Y, Fei G, Zhong C, Xu TLPowerful beneficial effects of benfotiamine on cognitive impairment and beta-amyloid deposition in amyloid precursor protein/presenilin-1 transgenic miceBrain.(2010 May)
      9.^Sun XJ, Zhao L, Zhao N, Pan XL, Fei GQ, Jin LR, Zhong CJBenfotiamine prevents increased β-amyloid production in HEK cells induced by high glucoseNeurosci Bull.(2012 Oct)
      11.^Montiel-Ruiz RM, Reyes-García G, Flores-Murrieta F, Déciga-Campos MAntinociceptive interaction between benfotiamine and resveratrol in capsaicin-induced lickingProc West Pharmacol Soc.(2009)
      12.^Sánchez-Ramírez GM, Caram-Salas NL, Rocha-González HI, Vidal-Cantú GC, Medina-Santillán R, Reyes-García G, Granados-Soto VBenfotiamine relieves inflammatory and neuropathic pain in ratsEur J Pharmacol.(2006 Jan 13)
      13.^Stracke H, Gaus W, Achenbach U, Federlin K, Bretzel RGBenfotiamine in diabetic polyneuropathy (BENDIP): results of a randomised, double blind, placebo-controlled clinical studyExp Clin Endocrinol Diabetes.(2008 Nov)
      14.^Ma H, Li SY, Xu P, Babcock SA, Dolence EK, Brownlee M, Li J, Ren JAdvanced glycation endproduct (AGE) accumulation and AGE receptor (RAGE) up-regulation contribute to the onset of diabetic cardiomyopathyJ Cell Mol Med.(2009 Aug)
      17.^Du Y, Kowluru A, Kern TSPP2A contributes to endothelial death in high glucose: inhibition by benfotiamineAm J Physiol Regul Integr Comp Physiol.(2010 Dec)
      18.^Stirban A, Negrean M, Stratmann B, Gawlowski T, Horstmann T, Götting C, Kleesiek K, Mueller-Roesel M, Koschinsky T, Uribarri J, Vlassara H, Tschoepe DBenfotiamine prevents macro- and microvascular endothelial dysfunction and oxidative stress following a meal rich in advanced glycation end products in individuals with type 2 diabetesDiabetes Care.(2006 Sep)
      20.^Syngle A, Vohra K, Garg N, Kaur L, Chand PAdvanced glycation end-products inhibition improves endothelial dysfunction in rheumatoid arthritisInt J Rheum Dis.(2012 Feb)
      21.^Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, Yorek MA, Beebe D, Oates PJ, Hammes HP, Giardino I, Brownlee MNormalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damageNature.(2000 Apr 13)
      22.^Hammes HP, Du X, Edelstein D, Taguchi T, Matsumura T, Ju Q, Lin J, Bierhaus A, Nawroth P, Hannak D, Neumaier M, Bergfeld R, Giardino I, Brownlee MBenfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathyNat Med.(2003 Mar)
      23.^Tang WH, Martin KA, Hwa JAldose reductase, oxidative stress, and diabetic mellitusFront Pharmacol.(2012)
      24.^Schenk G, Duggleby RG, Nixon PFProperties and functions of the thiamin diphosphate dependent enzyme transketolaseInt J Biochem Cell Biol.(1998 Dec)
      25.^Saito N, Kimura M, Kuchiba A, Itokawa YBlood thiamine levels in outpatients with diabetes mellitusJ Nutr Sci Vitaminol (Tokyo).(1987 Dec)
      27.^Schmid U, Stopper H, Heidland A, Schupp NBenfotiamine exhibits direct antioxidative capacity and prevents induction of DNA damage in vitroDiabetes Metab Res Rev.(2008 Jul-Aug)
      28.^Marchetti V, Menghini R, Rizza S, Vivanti A, Feccia T, Lauro D, Fukamizu A, Lauro R, Federici MBenfotiamine counteracts glucose toxicity effects on endothelial progenitor cell differentiation via Akt/FoxO signalingDiabetes.(2006 Aug)
      29.^Katare R, Oikawa A, Cesselli D, Beltrami AP, Avolio E, Muthukrishnan D, Munasinghe PE, Angelini G, Emanueli C, Madeddu PBoosting the pentose phosphate pathway restores cardiac progenitor cell availability in diabetesCardiovasc Res.(2012 Oct 16)
      31.^Alkhalaf A, Kleefstra N, Groenier KH, Bilo HJ, Gans RO, Heeringa P, Scheijen JL, Schalkwijk CG, Navis GJ, Bakker SJEffect of benfotiamine on advanced glycation endproducts and markers of endothelial dysfunction and inflammation in diabetic nephropathyPLoS One.(2012)
      35.^Oikawa A, Siragusa M, Quaini F, Mangialardi G, Katare RG, Caporali A, van Buul JD, van Alphen FP, Graiani G, Spinetti G, Kraenkel N, Prezioso L, Emanueli C, Madeddu PDiabetes mellitus induces bone marrow microangiopathyArterioscler Thromb Vasc Biol.(2010 Mar)
      36.^de Souza Pinto R, Castilho G, Paim BA, Machado-Lima A, Inada NM, Nakandakare ER, Vercesi AE, Passarelli MInhibition of macrophage oxidative stress prevents the reduction of ABCA-1 transporter induced by advanced glycated albuminLipids.(2012 May)
      37.^Passarelli M, Tang C, McDonald TO, O'Brien KD, Gerrity RG, Heinecke JW, Oram JFAdvanced glycation end product precursors impair ABCA1-dependent cholesterol removal from cellsDiabetes.(2005 Jul)
      38.^Isoda K, Folco EJ, Shimizu K, Libby PAGE-BSA decreases ABCG1 expression and reduces macrophage cholesterol efflux to HDLAtherosclerosis.(2007 Jun)
      41.^Schupp N, Dette EM, Schmid U, Bahner U, Winkler M, Heidland A, Stopper HBenfotiamine reduces genomic damage in peripheral lymphocytes of hemodialysis patientsNaunyn Schmiedebergs Arch Pharmacol.(2008 Sep)
      42.^Volkovová K, Barancoková M, Kazimírová A, Collins A, Raslová K, Smolková B, Horská A, Wsólová L, Dusinská MAntioxidant supplementation reduces inter-individual variation in markers of oxidative damageFree Radic Res.(2005 Jun)
      43.^Stirban A, Nandrean S, Kirana S, Götting C, Veresiu IA, Tschoepe DBenfotiamine counteracts smoking-induced vascular dysfunction in healthy smokersInt J Vasc Med.(2012)
      44.^Kihm LP, Müller-Krebs S, Klein J, Ehrlich G, Mertes L, Gross ML, Adaikalakoteswari A, Thornalley PJ, Hammes HP, Nawroth PP, Zeier M, Schwenger VBenfotiamine protects against peritoneal and kidney damage in peritoneal dialysisJ Am Soc Nephrol.(2011 May)
      46.^Alkhalaf A, Klooster A, van Oeveren W, Achenbach U, Kleefstra N, Slingerland RJ, Mijnhout GS, Bilo HJ, Gans RO, Navis GJ, Bakker SJA double-blind, randomized, placebo-controlled clinical trial on benfotiamine treatment in patients with diabetic nephropathyDiabetes Care.(2010 Jul)
      48.^Beltramo E, Nizheradze K, Berrone E, Tarallo S, Porta MThiamine and benfotiamine prevent apoptosis induced by high glucose-conditioned extracellular matrix in human retinal pericytesDiabetes Metab Res Rev.(2009 Oct)
      49.^Beltramo E, Buttiglieri S, Pomero F, Allione A, D'Alù F, Ponte E, Porta MA study of capillary pericyte viability on extracellular matrix produced by endothelial cells in high glucoseDiabetologia.(2003 Mar)
      50.^Beltramo E, Pomero F, Allione A, D'Alù F, Ponte E, Porta MPericyte adhesion is impaired on extracellular matrix produced by endothelial cells in high hexose concentrationsDiabetologia.(2002 Mar)
      52.^Hirschi KK, D'Amore PAPericytes in the microvasculatureCardiovasc Res.(1996 Oct)